$APMD News

Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apnimed: What We Know Heading Into The Feb PDUFA

Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Apnimed Q2 EPS $3.91 Beats $(0.34) Estimate, Sales $12.080M

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apnimed shares surge on bullish BofA initiation

LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50

Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60

Evercore ISI Group Initiates Coverage On Apnimed with Outperform Rating

B of A Securities Initiates Coverage On Apnimed with Buy Rating, Announces Price Target of $41

Apnimed (APMD) Joins The NASDAQ Composite Index

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO security released for quotation

Apnimed Announces Pricing of Upsized Initial Public Offering

Apnimed Seeks IPO For OSA Treatment Commercialization